EUR 2.66
(1.33%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 14.19 Million EUR | 0.0% |
2022 | - EUR | 0.0% |
2021 | - EUR | 0.0% |
2020 | - EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 4.1 Million EUR | 0.0% |
2024 Q3 | - EUR | -100.0% |
2024 Q1 | - USD | 0.0% |
2023 Q4 | - EUR | 0.0% |
2023 FY | - EUR | 0.0% |
2023 Q3 | - EUR | 0.0% |
2023 Q2 | - EUR | 0.0% |
2023 Q1 | - EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | - EUR | 0.0% |
2021 FY | - EUR | 0.0% |
2020 FY | - EUR | 0.0% |
2019 FY | - EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Atrys Health, S.A. | 201.56 Million EUR | 92.959% |
Biotechnologies Assets SA | 3.9 Million EUR | -263.103% |
Pharma Mar, S.A. | 158.15 Million EUR | 91.027% |
Laboratorios Farmaceuticos Rovi, S.A. | 829.5 Million EUR | 98.289% |